Search results for "Proton Pump Inhibitors"

showing 10 items of 42 documents

Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibrobla…

2018

Abstract Background Fibrosis may be considered the hallmark of systemic sclerosis (SSc), the end stage triggered by different pathological events. Transforming growth factor-β (TGF-β) and platelet-derived growth factor BB (PDGF-BB) are profibrotic molecules modulating myofibroblast differentiation and proliferation, respectively. There is evidence linking CD248 with these two molecules, both highly expressed in patients with SSc, and suggesting that CD248 may be a therapeutic target for several diseases. The aim of this work was to evaluate the expression of CD248 in SSc skin and its ability to modulate SSc fibrotic process. Methods After ethical approval was obtained, skin biopsies were co…

0301 basic medicineMalelcsh:Diseases of the musculoskeletal systemProton Pump InhibitorFibrosiCellular differentiationmedicine.medical_treatmentSystemic sclerosiFibrosisImmunology and AllergyMedicineMyofibroblastsskin and connective tissue diseasesCells CulturedSkinintegumentary systemCell DifferentiationMiddle AgedMesenchymal Stem CellBenzamidesSystemic sclerosisFemaleMyofibroblastResearch ArticleHumanAdultStromal cellImmunology03 medical and health sciencesYoung AdultRheumatologyBenzamideAntigens CDAntigens NeoplasmHumansGene silencingCell ProliferationMyofibroblastScleroderma Systemicbusiness.industryGrowth factorMesenchymal stem cellStromal CellMesenchymal Stem CellsProton Pump Inhibitorsmedicine.diseaseFibrosisCD248Settore MED/16 - Reumatologia030104 developmental biologyCancer researchStromal Cellslcsh:RC925-935CD248; Fibrosis; Systemic sclerosis; Rheumatology; Immunology and Allergy; ImmunologybusinessTransforming growth factor
researchProduct

Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells

2016

Recent evidence has reported that proton pump inhibitors (PPIs) can exert antineoplastic effects through the disruption of pH homeostasis by inhibiting vacuolar ATPase (H+-VATPase), a proton pump overexpressed in several tumor cells, but this aspect has not been deeply investigated in EAC yet. In the present study, the expression of H+-VATPase was assessed through the metaplasia-dysplasia-adenocarcinoma sequence in Barrett’s esophagus (BE) and the antineoplastic effects of PPIs and cellular mechanisms involved were evaluated in vitro. H+-VATPase expression was assessed by immunohistochemistry in paraffined-embedded samples or by immunofluorescence in cultured BE and EAC cell lines. Cells we…

0301 basic medicineesophageal adenocarcinomaIntracellular pHvacuolar ATPaseBiologymedicine.disease_causeBarrett's esophagus03 medical and health sciencesmedicineBarrett’s esophagusCytotoxic T cellPharmacology (medical)Original Researchreactive oxygen speciesPharmacologychemistry.chemical_classificationReactive oxygen specieslcsh:RM1-950AutophagyProton Pump InhibitorsIn vitrolcsh:Therapeutics. Pharmacology030104 developmental biologyBiochemistrychemistryCell cultureApoptosisCancer researchEsophageal adenocarcinomaproton pump inhibitorsReactive Oxygen SpeciesOxidative stressFrontiers in Pharmacology
researchProduct

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

2021

Background & Aims A number of double, triple, and quadruple therapies have been proposed as first-line empiric treatments for Helicobacter pylori infection. However, knowledge of their worldwide and regional comparative efficacy is lacking. We examined the comparative effectiveness of all empirically used first-line regimens tested against standard triple treatment using a network meta-analysis of published randomized controlled trials. Methods Data extracted from eligible randomized controlled trials were entered into a Bayesian network meta-analysis to investigate the comparative efficacy of H pylori infection empiric first-line regimens and to explore their effectiveness rank order. The …

0301 basic medicinemedicine.medical_specialtyComparative Effectiveness ResearchTime FactorsEfficacyVonoprazanSettore MED/12 - GASTROENTEROLOGIANetwork Meta-Analysislaw.inventionHelicobacter Infections03 medical and health sciences0302 clinical medicineRandomized controlled trialDrug TherapyLevofloxacinlawInternal medicinemedicineHumansFirst-Line RegimensRandomized Controlled Trials as TopicHepatologybiologyHelicobacter pyloribusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyBayes TheoremProton Pump InhibitorsOdds ratioHelicobacter pyloribiology.organism_classificationConfidence intervalAnti-Bacterial AgentsTreatmentRegimen030104 developmental biologyTreatment OutcomeMeta-analysisCombination030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drug
researchProduct

Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study

2020

Bone fractures are a frequent complication in patients with cirrhosis. Proton pump inhibitors (PPIs) are among the most frequently prescribed medications and may impair bone quality and quantity.To investigate whether PPI use predisposes patients with cirrhosis to bone fractures.We performed a population-based case-control study exploring a sample of patients with cirrhosis derived from the Disease Analyzer database. In total, 1795 cirrhotic patients with fractures were compared to 10 235 cirrhotic patients without fractures. PPI use overall and the cumulative PPI dose 5 years prior to the index date were analysed. To estimate the association between PPI use and fractures, logistic regressi…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisAdolescentPopulationDiseaseLogistic regressionRisk AssessmentFractures BoneYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)030212 general & internal medicineYoung adulteducationAgedAged 80 and overeducation.field_of_studyHepatologybusiness.industryGastroenterologyCase-control studyProton Pump InhibitorsMiddle Agedmedicine.diseaseCase-Control StudiesFemale030211 gastroenterology & hepatologyRisk assessmentbusinessComplicationAlimentary Pharmacology & Therapeutics
researchProduct

The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients

2015

Background Proton pump inhibitors (PPIs) are among the most misused drugs both at the community and hospital level. Recently, possible risks have been underscored, suggesting the importance of limiting PPI use to proven indications. Objective To survey the appropriateness of PPI use in a University hospital in Italy. Setting Azienda Ospedaliera Universitaria Policlinico ‘P. Giaccone’, in Palermo, Italy. Method A one day-observational study, reviewing patients’ medical records to identify treatments with PPIs and the indications for their use. After discharge, a subgroup of the cohort was followed up to assess the continuation of therapy at home. Appropriateness was evaluated according to th…

AdultMaleDrug UtilizationDrugmedicine.medical_specialtyIcu patientsmedia_common.quotation_subjectPharmaceutical ScienceInappropriate PrescribingPharmacyPharmacyProton pump inhibitorToxicologyHospitals UniversityHospitalmedicineDrug utilizationHumansPharmacology (medical)Stomach UlcerMedical prescriptionIntensive care medicineAgedmedia_commonPharmacologybusiness.industryMedical recordStress ulcerProton Pump InhibitorsMiddle Agedmedicine.diseasePatient DischargeHospitalizationTherapeutic appropriateneItalyPractice Guidelines as TopicCohortSettore BIO/14 - FarmacologiaFemaleGuideline Adherencebusiness
researchProduct

Efficacy of naproxen with or without esomeprazole for pain and inflammation in patients after bilateral third molar extractions: a double blinded cro…

2017

Background Using a double-blinded randomized crossover design, this study aimed to evaluate acute postoperative pain management, swelling and trismus in 46 volunteers undergoing extractions of the two lower third molars, in similar positions, at two different appointments who consumed a tablet of either NE (naproxen 500 mg + esomepraz ole 20 mg) or only naproxen (500 mg) every 12 hours for 4 days. Material and Methods Parameters were analyzed: self-reported pain intensity using a visual analog scale (VAS) pre- and postoperative mouth opening; incidence, type and severity of adverse reactions; total quantity consumed of rescue medication; and pre- and postoperative swelling. Results Female v…

AdultMaleMolarNaproxenmedicine.medical_specialtyAdolescentVisual analogue scaleTrismuslaw.inventionEsomeprazoleYoung Adult03 medical and health sciencesCOMPLICAÇÕES PÓS-OPERATÓRIASNaproxen0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawHumansPain ManagementMedicineGeneral DentistryInflammationPain PostoperativeCross-Over Studiesbusiness.industryResearchAnti-Inflammatory Agents Non-SteroidalEsomeprazoleProton Pump Inhibitors:CIENCIAS MÉDICAS [UNESCO]Crossover studySurgeryTreatment OutcomeOtorhinolaryngology030220 oncology & carcinogenesisAnesthesiaUNESCO::CIENCIAS MÉDICASTooth ExtractionDrug Therapy CombinationFemaleMolar ThirdSurgeryOral Surgerymedicine.symptombusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: An Italian, multicentre study

2009

Abstract Background/Aim Data on management and long-term follow-up of Helicobacter pylori -associated MALT-lymphoma in clinical practice are scanty. We evaluate the long-term efficacy of H. pylori eradication on low-grade MALT-lymphoma, and the efficacy of further therapies in refractory patients. Methods This study enrolled patients with stages I–II 1 MALT-lymphoma and H. pylori infection. H. pylori eradication was attempted in all patients. Patients with lymphoma persistence or progression following H. pylori treatments received further lymphoma treatments. Both 5-year and disease-free survivals were calculated. Results Sixty patients (stage I/II 1 : 50/10) were followed up for a median t…

AdultMaleVincristinemedicine.medical_specialtyCyclophosphamideSettore MED/12 - GASTROENTEROLOGIAGastric maltomamanagementKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalHelicobacter InfectionsYoung AdultStomach Neoplasmsimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultCyclophosphamideAgedRetrospective StudiesAged 80 and overHelicobacter pyloriHepatologybiologybusiness.industryGastroenterologyProton Pump InhibitorsMALT lymphomaRetrospective cohort studyLymphoma B-Cell Marginal ZoneMiddle AgedHelicobacter pyloribiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsLymphomaSurgeryItalyDoxorubicinVincristinePrednisoneFemalebusinessFollow-Up Studiesmedicine.drug
researchProduct

Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 y…

2020

Background According to recent estimates 80% of Latvian population is infected with Helicobacter pylori thus their susceptibility to numerous gastric tract diseases is increased. The 1st line H. pylori eradication therapy includes treatment with clarithromycin in combination with amoxicillin or metronidazole and a proton pump inhibitor. However, potential adverse events caused by such therapies to microbiome are insufficiently studied. Objective This study aimed to evaluate the long-term effect of H. pylori eradication on human gastrointestinal tract (GIT) microbiome. Methods The assessment of H pylori eradication impact on GIT microbiome was done by analyzing 120 samples acquired from 60 s…

AdultMalemedicine.medical_specialtyPopulationGastroenterologyHelicobacter Infections03 medical and health sciences0302 clinical medicineInternal medicineClarithromycinClarithromycinMetronidazolemedicineHumansMicrobiomeeducationeducation.field_of_studybiologybusiness.industryGastroenterologyAmoxicillinProton Pump InhibitorsGeneral MedicineHelicobacter pyloriAmoxicillinMiddle Agedbiology.organism_classificationLatviaAnti-Bacterial AgentsGastrointestinal MicrobiomeMetronidazoleInfectious Diseases030220 oncology & carcinogenesis030211 gastroenterology & hepatologyEnterotypeDrug Therapy CombinationFemaleSample collectionbusinessmedicine.drugHelicobacterREFERENCES
researchProduct

The effects of omeprazole 20 and 40 mg twice daily on intragastric acidity in duodenal ulcer patients.

1996

BACKGROUND: The combination of omeprazole with amoxycillin or clarithromycin is used as treatment against Helicobacter pylori. It seems likely that the antibacterial activity of the antibiotic may be improved by increasing gastric pH towards neutrality, and a twice daily regimen of omeprazole is probably needed. AIM: To assess the effects of twice daily administration of omeprazole 20 and 40 mg. METHODS: Twelve duodenal ulcer patients in remission were randomized to receive in single-blind fashion either placebo, omeprazole 20 mg or omeprazole 40 mg twice daily (08.00 and 20.00 h). On the sixth day of dosing they underwent 24-h gastric pH-metry. RESULTS: Omeprazole 20 and 40 mg b.d. produce…

AdultMalemedicine.medical_specialtymedicine.drug_classProton-pump inhibitorGastroenterologyHelicobacter InfectionsGastric AcidInternal medicineClarithromycinmedicineHumansSingle-Blind MethodPharmacology (medical)Enzyme InhibitorsOmeprazoleGastric Acidity DeterminationCross-Over StudiesHelicobacter pyloriHepatologybiologybusiness.industryStomachGastroenterologyProton Pump InhibitorsGastric Acidity DeterminationMiddle AgedHelicobacter pyloribiology.organism_classificationCrossover studyCircadian Rhythmmedicine.anatomical_structureDuodenal UlcerDuodenumFemalebusinessOmeprazolemedicine.drugAlimentary Pharmacology & Therapeutics
researchProduct

Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in I…

2021

Background: Information on the management of Helicobacter (H.) pylori infection by gastroenterologists and gastroenterology fellows are scarce. We aimed to assess practice of gastroenterologists and gastroenterology fellows and their adherence to guidelines for diagnosis and treatment of H. pylori infection in Italy. Materials and Methods: All gastroenterologists and gastroenterology fellows attending the National Congress of Digestive Diseases - FISMAD were invited to fill-in an on-line questionnaire. The questionnaire included questions on the diagnosis and treatment of H. pylori infection. Results: A total of 279 gastroenterologists and 61 gastroenterology fellows participated to the stu…

Background informationHelicobacter pylori infectionmedicine.medical_specialtygenetic structuresdiagnosisgastroenterology fellowGastroenterologyHelicobacter pylori; diagnosis; gastroenterologists; gastroenterology fellows; guidelines; treatment; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy Combination; Humans; Proton Pump Inhibitors; Surveys and Questionnaires; Gastroenterologists; Gastroenterology; Helicobacter Infections; Helicobacter pyloriHelicobacter InfectionsDrug TherapyClarithromycinInternal medicineClarithromycinSurveys and QuestionnairesMedicineHumansguidelinesbiologyHelicobacter pyloritreatmentbusiness.industryGastroenterologistsGastroenterologyAmoxicillinProton Pump InhibitorsGeneral MedicineHelicobacter pyloribiology.organism_classificationeye diseasesAnti-Bacterial AgentsdiagnosiInfectious Diseasesgastroenterology fellowsThird lineCombinationDrug Therapy CombinationgastroenterologistEducational interventionsbusinessguidelineBismuthmedicine.drug
researchProduct